| Textbook of Medical Physiology_-E-book I Khurana, A Khurana, NG Kowlgi Elsevier Health Sciences, 2019 | 163 | 2019 |
| MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) A Khurana, DA Shafer OncoTargets and therapy, 2903-2910, 2019 | 87 | 2019 |
| Medical physiology for undergraduate students-E-book I Khurana Elsevier Health Sciences, 2018 | 40 | 2018 |
| Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review EJ Bataillard, CY Cheah, MJ Maurer, A Khurana, TA Eyre, TC El-Galaly Blood advances 5 (9), 2426-2437, 2021 | 35 | 2021 |
| Textbook of human physiology for dental students I Khurana Elsevier Health Sciences, 2012 | 34 | 2012 |
| Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? O Saifi, WG Breen, SC Lester, WG Rule, B Stish, A Rosenthal, J Munoz, ... Radiotherapy and Oncology 166, 171-179, 2022 | 32 | 2022 |
| Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review L Mei, A Khurana, T Al-Juhaishi, A Faber, F Celi, S Smith, S Boikos Hormone and Metabolic Research 51 (07), 451-457, 2019 | 26 | 2019 |
| A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy S Gouni, AC Rosenthal, JL Crombie, A Ip, MK Kamdar, B Hess, L Feng, ... Blood Advances 6 (9), 2757-2762, 2022 | 22 | 2022 |
| Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT WG Breen, MA Hathcock, JR Young, RO Kowalchuk, R Bansal, ... Journal of hematology & oncology 15 (1), 36, 2022 | 22 | 2022 |
| Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era A Khurana, M Novo, GS Nowakowski, KM Ristow, RJ Spinner, CH Hunt, ... Blood advances 5 (5), 1379-1387, 2021 | 22 | 2021 |
| Textbook of Medical Physiology second edition/Indu Khurana K Indu Elsevier India, 2015 | 19 | 2015 |
| Therapy-related myeloid neoplasms in lymphoma survivors: reducing risks T Al-Juhaishi, A Khurana, D Shafer Best Practice & Research Clinical Haematology 32 (1), 47-53, 2019 | 18 | 2019 |
| Impact of organ function–based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind? A Khurana, R Mwangi, GS Nowakowski, TM Habermann, SM Ansell, ... Journal of clinical oncology 39 (15), 1641, 2021 | 16 | 2021 |
| Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects! A Khurana, CA Dasanu Journal of Oncology Pharmacy Practice 21 (6), 443-450, 2015 | 16 | 2015 |
| Analysis and impact of a multidisciplinary lymphoma virtual tumor board TM Habermann, A Khurana, R Lentz, JJ Schmitz, AG von Bormann, ... Leukemia & lymphoma 61 (14), 3351-3359, 2020 | 15 | 2020 |
| Role of microenvironment in non-Hodgkin lymphoma: understanding the composition and biology A Khurana, SM Ansell The Cancer Journal 26 (3), 206-216, 2020 | 15 | 2020 |
| The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel K Wudhikarn, R Bansal, A Khurana, MA Hathcock, NN Bennani, J Paludo, ... Blood cancer journal 11 (7), 124, 2021 | 14 | 2021 |
| Allogeneic chimeric antigen receptor therapy in lymphoma A Khurana, Y Lin Current treatment options in oncology 23 (2), 171-187, 2022 | 12 | 2022 |
| Hepatitis associated aplastic anemia: case report and discussion. A Khurana, CA Dasanu Connecticut Medicine 78 (8), 2014 | 11 | 2014 |
| Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study DA Qualls, N Lambert, PF Caimi, M Merrill, P Pullarkat, RC Godby, ... Blood 142 (26), 2327-2331, 2023 | 10 | 2023 |
Gurukripa N. Kowlgi, MBBS, MS, FAC...Assistant Professor of Medicine, Mayo Clinic, Rochester, MNBestätigte E-Mail-Adresse bei mayo.edu
